THURSDAY, June 13, 2019 -- A 14-day course of an Fc receptor-nonbinding anti-CD3 monoclonal antibody, teplizumab, can delay progression to type 1 diabetes in individuals at high risk, according to a study published online June 9 in the New England...
Original Article: ADA: Teplizumab Can Delay T1DM Progression in Those at Risk